A New Positive Control Option in the UUO Model: Dapagliflozin
We have confirmed the renoprotective effect of the SGLT2 inhibitor dapagliflozin (20 mg/kg, oral administration) in the unilateral ureteral obstruction (UUO) model. This finding enables us to offer dapagliflozin, in addition to the conventional ALK5 inhibitor, as a new positive control option in the UUO model.
Dapagliflozin has already established clinical efficacy in chronic kidney disease and heart failure, and our data demonstrate consistent renoprotective effects in the UUO model as well. This enhances the reliability of the evaluation system for the development of novel renoprotective drugs and provides our clients with a practical option for comparative studies and compound screening.
